Connections Northwest Biotherapeutics, Inc. Börse Stuttgart

NBYB

US66737P6007

Biotechnology & Medical Research

Delayed Börse Stuttgart 05:31:31 2026-09-29 EDT			5-day change	1st Jan Change
0.1250 ^EUR	-4.58%		-21.88%	-39.32%

08-14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-06	Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration	CI

1

Listed companies

0

Private companies

24

Insiders

Relation chart of related listed companies: Northwest Biotherapeutics, Inc.

Active Relations

Past Relations

Related listed companies: Northwest Biotherapeutics, Inc.

ONCOTELIC THERAPEUTICS, INC.

Anthony Maida

Active Relations

Past Relations

Connection statistics

Active

Inactive

Listed companies

Private companies

Activities of related companies

Biotechnology

Countries of related companies

United States

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees

105

Sector

Biotechnology & Medical Research

More about the company